Biography

Dr Bowerman (@BowermanNMD) is a Lecturer in Bioscience at the School of Medicine and a group member of the Wolfson Centre for Inherited Neuromuscular Disease in Oswestry.

Dr Bowerman completed her Ph.D. (2006-2012) in Dr Rashmi Kothary's laboratory (Ottawa Hospital Research Institute (OHRI)/University of Ottawa, Canada) where she held a CIHR Frederick Banting and Charles Best doctoral award and received the OHRI Dr. Ronald G. Worton Researcher in Training Award. Dr Bowerman then joined Dr Cedric Raoul's laboratory at the Institut des Neurosciences de Montpellier in France as an EMBO Long-Term Fellow (2012-2014). From 2014-2016, Dr Bowerman was a postdoctoral research assistant at the University of Oxford in Professor Matthew Wood's group. In October 2015, Dr Bowerman was the recipient of a Junior Research Fellowship at Somerville College, University of Oxford (2015-2017). In January 2016, Dr Bowerman was awarded and SMA Trust Career Development Fellowship at the University of Oxford.

Research and scholarship

The central thematic of our research programme is to identify novel pathological pathways that contribute to the pathophysiology of rare diseases and to investigate novel therapeutic approaches using a combination of omics, bioinformatics and drug repurposing strategies.

More information on our research projects and funding can be found here.

Teaching

Dr Bowerman contributes to various elements of the:

  1. MBChB degree, School of Medicine, Keele University, UK
  2. LSC-20016 Module, School of Life Sciences, Keele University, UK
  3. Physiology of Neuromusculoskeletal Tissue Module, School of Applied Health Professions, Keele University, UK
  4. Physician Associate Studies M.Sc., Keele University, UK
  5. Paramedic Science with Integrated Master’s M.Sci., Keele University, Keele
  6. M.Sc. Neuroscience degree, University of Oxford, UK

More information on our publications can be found on my website.

Selected Publications

  • Benlefki S, Younes R, Challuau D, Bernard-Marissal N, Hilaire C, Scamps F, Bowerman M, Kothary R, Schneider B, Raoul C. 2022. Differential effect of Fas activation on spinal muscular atrophy motoneuron death and induction of axonal growth. doi>
  • Owen S, Soltic D, Synowsky S, Crompton E, Yanez-Munoz R, Schneider B, Shorrock H, Shirran S, Gillingwater T, Bowerman M, Fuller H. 2021. Proteins associated with the sarcomere and costamere in hearts are dysregulated in two mouse models of spinal muscular atrophy. NEUROMUSCULAR DISORDERS (pp. S131-S132, vol. 31). link> doi>
  • Betts CA, Jagannath A, van Westering TLE, Bowerman M, Banerjee S, Meng J, Falzarano MS, Cravo L, McClorey G, Meijboom KE, Bhomra A, Lim WF, Rinaldi C, Counsell JR, Chwalenia K, O'Donovan E, Saleh AF, Gait MJ, Morgan JE, Ferlini A, Foster RG, Wood MJ. 2021. Dystrophin involvement in peripheral circadian SRF signalling. Life Sci Alliance, vol. 4(10). link> doi> full text>
  • Meijboom KE, Volpato V, Monzón-Sandoval J, Hoolachan JM, Hammond SM, Abendroth F, de Jong OG, Hazell G, Ahlskog N, Wood MJ, Webber C, Bowerman M. 2021. Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. JCI Insight, vol. 6(13). link> doi> full text>
  • Hoolachan J, Okoh M, Sutton E, Walter LM, Claus P, Tonge D, Bowerman M. 2021. A transcriptomic-based drug repurposing strategy for the identification of new SMN-independent skeletal muscle treatments for spinal muscular atrophy. FEBS Open Bio (p. 351, vol. 11). Elsevier. link> doi> link>

Full Publications Listshow

Journal Articles

  • Benlefki S, Younes R, Challuau D, Bernard-Marissal N, Hilaire C, Scamps F, Bowerman M, Kothary R, Schneider B, Raoul C. 2022. Differential effect of Fas activation on spinal muscular atrophy motoneuron death and induction of axonal growth. doi>
  • Betts CA, Jagannath A, van Westering TLE, Bowerman M, Banerjee S, Meng J, Falzarano MS, Cravo L, McClorey G, Meijboom KE, Bhomra A, Lim WF, Rinaldi C, Counsell JR, Chwalenia K, O'Donovan E, Saleh AF, Gait MJ, Morgan JE, Ferlini A, Foster RG, Wood MJ. 2021. Dystrophin involvement in peripheral circadian SRF signalling. Life Sci Alliance, vol. 4(10). link> doi> full text>
  • Meijboom KE, Volpato V, Monzón-Sandoval J, Hoolachan JM, Hammond SM, Abendroth F, de Jong OG, Hazell G, Ahlskog N, Wood MJ, Webber C, Bowerman M. 2021. Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. JCI Insight, vol. 6(13). link> doi> full text>
  • Watson K, Boukhloufi I, Bowerman M, Parson SH. 2021. The relationship between body composition, fatty acid metabolism and diet in spinal muscular atrophy. Brain Sciences, Article 131, vol. 11(2). doi> link> full text>
  • Winkelsas AM, Grunseich C, Harmison GG, Chwalenia K, Rinaldi C, Hammond SM, Johnson K, Bowerman M, Arya S, Talbot K, Wood MJ, Fischbeck KH. 2021. Targeting the 5’ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy. Molecular Therapy : Nucleic Acids, 731-742, vol. 23. doi> link> full text>
  • Rademacher S, Detering NT, Schüning T, Lindner R, Santonicola P, Wefel I-M, Dehus J, Walter LM, Brinkmann H, Niewienda A, Janek K, Varela MA, Bowerman M, Di Schiavi E, Claus P. 2020. A Single Amino Acid Residue Regulates PTEN-Binding and Stability of the Spinal Muscular Atrophy Protein SMN. Cells, vol. 9(11). link> doi> full text>
  • Bowerman M. 2020. Recent Advances and Future Perspectives in the Development of Therapeutic Approaches for Neurodegenerative Diseases. Brain Sci, vol. 10(9). link> doi> full text>
  • Ahlskog N, Hayler D, Krueger A, Kubinski S, Claus P, Hammond SM, Wood MJA, Yáñez-Muñoz RJ, Bowerman M. 2019. Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mice. Gene Ther, 505-515, vol. 27(10-11). link> doi> full text>
  • Benlefki S, Sanchez-Vicente A, Milla V, Lucas O, Soulard C, Younes R, Gergely C, Bowerman M, Raoul C, Scamps F, Hilaire C. 2020. Expression of ALS-linked SOD1 Mutation in Motoneurons or Myotubes Induces Differential Effects on Neuromuscular Function In vitro. Neuroscience, 33-43, vol. 435. link> doi> full text>
  • Hoolachan J, Sutton E, Bowerman M. 2019. Teaching an old drug new tricks: Repositioning strategies for spinal muscular atrophy. Future Neurology, vol. 14(3). doi> link> full text>
  • Ahlskog N, Hayler D, Krueger A, Kubinski S, Claus P, Yáñez-Muñoz R, Bowerman M. 2019. Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mice. doi> full text>
  • Deguise M-O, Baranello G, Mastella C, Beauvais A, Michaud J, Leone A, De Amicis R, Battezzati A, Dunham C, Selby K, Warman Chardon J, McMillan HJ, Huang Y-T, Courtney NL, Mole AJ, Kubinski S, Claus P, Murray LM, Bowerman M, Gillingwater TH, Bertoli S, Parson SH, Kothary R. 2019. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Ann Clin Transl Neurol, 1519-1532, vol. 6(8). link> doi> full text>
  • Bowerman M. 2019. Funding for spinal muscular atrophy research must continue. Future Neurology. doi> full text>
  • Šoltić D, Bowerman M, Stock J, Shorrock HK, Gillingwater TH, Fuller HR. 2018. Multi-Study Proteomic and Bioinformatic Identification of Molecular Overlap between Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). Brain Sci, vol. 8(12). link> doi> full text>
  • Walter LM, Koch CE, Betts CA, Ahlskog N, Meijboom KE, van Westering TLE, Hazell G, Bhomra A, Claus P, Oster H, Wood MJA, Bowerman M. 2018. Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice. Hum Mol Genet, 3582-3597, vol. 27(20). link> doi> full text>
  • Walter LM, Deguise M-O, Meijboom KE, Betts CA, Ahlskog N, van Westering TLE, Hazell G, McFall E, Kordala A, Hammond SM, Abendroth F, Murray LM, Shorrock HK, Prosdocimo DA, Haldar SM, Jain MK, Gillingwater TH, Claus P, Kothary R, Wood MJA, Bowerman M. 2018. Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. EBioMedicine, 226-242, vol. 31. link> doi> full text>
  • Bowerman M, Murray LM, Scamps F, Schneider BL, Kothary R, Raoul C. 2018. Pathogenic commonalities between spinal muscular atrophy and amyotrophic lateral sclerosis: Converging roads to therapeutic development. Eur J Med Genet, 685-698, vol. 61(11). link> doi> full text>
  • Bowerman M, Salsac C, Bernard V, Soulard C, Dionne A, Coque E, Benlefki S, Hince P, Dion PA, Butler-Browne G, Camu W, Bouchard J-P, Delpire E, Rouleau GA, Raoul C, Scamps F. 2017. KCC3 loss-of-function contributes to Andermann syndrome by inducing activity-dependent neuromuscular junction defects. Neurobiol Dis, 35-48, vol. 106. link> doi> full text>
  • Wood MJA, Talbot K, Bowerman M. 2017. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Hum Mol Genet, R151-R159, vol. 26(R2). link> doi> full text>
  • Bowerman M, Becker CG, Yáñez-Muñoz RJ, Ning K, Wood MJA, Gillingwater TH, Talbot K, UK SMA Research Consortium. 2017. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech, 943-954, vol. 10(8). link> doi> full text>
  • Hammond SM, Hazell G, Shabanpoor F, Saleh AF, Bowerman M, Sleigh JN, Meijboom KE, Zhou H, Muntoni F, Talbot K, Gait MJ, Wood MJA. 2016. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A, 10962-10967, vol. 113(39). link> doi> full text>
  • Rousset M, Cens T, Menard C, Bowerman M, Bellis M, Brusés J, Raoul C, Scamps F, Charnet P. 2015. Regulation of neuronal high-voltage activated Ca(V)2 Ca(2+) channels by the small GTPase RhoA. Neuropharmacology, 201-209, vol. 97. link> doi>
  • Bowerman M, Salsac C, Coque E, Eiselt É, Deschaumes RG, Brodovitch A, Burkly LC, Scamps F, Raoul C. 2015. Tweak regulates astrogliosis, microgliosis and skeletal muscle atrophy in a mouse model of amyotrophic lateral sclerosis. Hum Mol Genet, 3440-3456, vol. 24(12). link> doi>
  • Coque E, Raoul C, Bowerman M. 2014. ROCK inhibition as a therapy for spinal muscular atrophy: understanding the repercussions on multiple cellular targets. Front Neurosci, 271, vol. 8. link> doi>
  • Scamps F, Sangari S, Bowerman M, Rousset M, Bellis M, Cens T, Charnet P. 2015. Nerve injury induces a Gem-GTPase-dependent downregulation of P/Q-type Ca2+ channels contributing to neurite plasticity in dorsal root ganglion neurons. Pflugers Arch, 351-366, vol. 467(2). link> doi>
  • Otsmane B, Moumen A, Aebischer J, Coque E, Sar C, Sunyach C, Salsac C, Valmier J, Salinas S, Bowerman M, Raoul C. 2014. Somatic and axonal LIGHT signaling elicit degenerative and regenerative responses in motoneurons, respectively. EMBO Rep, 540-547, vol. 15(5). link> doi>
  • Bowerman M, Michalski J-P, Beauvais A, Murray LM, DeRepentigny Y, Kothary R. 2014. Defects in pancreatic development and glucose metabolism in SMN-depleted mice independent of canonical spinal muscular atrophy neuromuscular pathology. Hum Mol Genet, 3432-3444, vol. 23(13). link> doi>
  • Bowerman M, Vincent T, Scamps F, Perrin FE, Camu W, Raoul C. 2013. Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis. Front Cell Neurosci, 214, vol. 7. link> doi>
  • Bowerman M, Swoboda KJ, Michalski J-P, Wang G-S, Reeks C, Beauvais A, Murphy K, Woulfe J, Screaton RA, Scott FW, Kothary R. 2012. Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann Neurol, 256-268, vol. 72(2). link> doi>
  • Bowerman M, Murray LM, Boyer JG, Anderson CL, Kothary R. 2012. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med, 24, vol. 10. link> doi>
  • Bowerman M, Murray LM, Beauvais A, Pinheiro B, Kothary R. 2012. A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology. Neuromuscul Disord, 263-276, vol. 22(3). link> doi>
  • Boyer JG, Bowerman M, Kothary R. 2010. The many faces of SMN: deciphering the function critical to spinal muscular atrophy pathogenesis. Future Neurology, 873-890, vol. 5(6). doi>
  • Bowerman M, Beauvais A, Anderson CL, Kothary R. 2010. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum Mol Genet, 1468-1478, vol. 19(8). link> doi>
  • Bowerman M, Anderson CL, Beauvais A, Boyl PP, Witke W, Kothary R. 2009. SMN, profilin IIa and plastin 3: a link between the deregulation of actin dynamics and SMA pathogenesis. Mol Cell Neurosci, 66-74, vol. 42(1). link> doi>
  • Mattis VB, Bowerman M, Kothary R, Lorson CL. 2008. A SMNDelta7 read-through product confers functionality to the SMNDelta7 protein. Neurosci Lett, 54-58, vol. 442(1). link> doi>
  • Bowerman M, Shafey D, Kothary R. 2007. Smn depletion alters profilin II expression and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity. J Mol Neurosci, 120-131, vol. 32(2). link> doi>

Chapters

  • Bowerman M, Vincent T, Scamps F, Camu W, Raoul C. The Neuroinflammation in the Physiopathology of Amyotrophic Lateral Sclerosis. In Current Advances in Amyotrophic Lateral Sclerosis. InTech. doi>

Other

  • Owen S, Soltic D, Synowsky S, Crompton E, Yanez-Munoz R, Schneider B, Shorrock H, Shirran S, Gillingwater T, Bowerman M, Fuller H. 2021. Proteins associated with the sarcomere and costamere in hearts are dysregulated in two mouse models of spinal muscular atrophy. NEUROMUSCULAR DISORDERS (pp. S131-S132, vol. 31). link> doi>
  • Hoolachan J, Okoh M, Sutton E, Walter LM, Claus P, Tonge D, Bowerman M. 2021. A transcriptomic-based drug repurposing strategy for the identification of new SMN-independent skeletal muscle treatments for spinal muscular atrophy. FEBS Open Bio (p. 351, vol. 11). Elsevier. link> doi> link>

Roles

School of Medicine
David Weatherall building
University Road
Keele University
Staffordshire
ST5 5BG